董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hilda Scharen Guivel | 女 | Director | 54 | 16.24万美元 | 0.86 | 2025-09-02 |
| Joe Kiani | 男 | Director | 61 | 17.20万美元 | 未持股 | 2025-09-02 |
| Roger Susi | 男 | Director,Chairman of the Board, President and Chief Executive Officer | 71 | 78.06万美元 | 442.80 | 2025-09-02 |
| James Hawkins | 男 | Director | 69 | 14.99万美元 | 2.96 | 2025-09-02 |
| Monty Allen | 男 | Director | 72 | 16.99万美元 | 2.10 | 2025-09-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Glenn | 男 | Chief Financial Officer | 63 | 61.00万美元 | 1.43 | 2025-09-02 |
| Jeffery Chiprin | 男 | Chief Commercial Officer | 59 | 52.94万美元 | 未持股 | 2025-09-02 |
| Roger Susi | 男 | Director,Chairman of the Board, President and Chief Executive Officer | 71 | 78.06万美元 | 442.80 | 2025-09-02 |
董事简历
中英对照 | 中文 | 英文- Hilda Scharen Guivel
-
Hilda Scharen Guivel，自2022年起任职。Scharen-Guivel女士目前担任圣安东尼医院董事会成员，该医院自2025年1月起成为社区拥有的Baycare卫生系统的一部分。她自2025年2月起担任圣安东尼（i）临床卓越委员会成员，自2024年2月起担任（ii）财务委员会成员。从2022年1月至今，Scharen-Guivel女士在坦帕湾技术孵化器（TBTI）专业委员会任职，并担任南佛罗里达大学（“USF”）和USF Connect的特邀发言人。Scharen-Guivel女士于2017年至2022年担任美国食品和药物管理局（“FDA”）器械和放射健康中心的项目主任，在那里她领导并实施了新的医疗器械开发工具计划。她的职业生涯跨越了25年，在多个联邦机构任职，包括FDA、卫生与公众服务部和美国国立卫生研究院。她于2022年从现役退役，担任美国公共卫生服务队长。Scharen-Guivel女士在美国天主教大学获得生物医学工程学士和工程学硕士学位。
Hilda Scharen Guivel,has served on Board since 2022. Ms. Scharen-Guivel currently serves on the Board of Trustees of St. Anthony's Hospital, part of a community-owned Baycare Health System since January 2025. She has been serving on St. Anthony's (i) Clinical Excellence Committee since February 2025 and (ii) Finance Committee since February 2024. From January 2022 to present, Ms. Scharen-Guivel serves on the Tampa Bay Technology Incubator (TBTI) Council of Professionals, and Guest Speaker to the University of South Florida ("USF") and USF Connect. Ms. Scharen-Guivel served as Program Director of the U.S. Food and Drug Administration (the "FDA") Center of Devices and Radiological Health from 2017 to 2022, where she led and implemented the new Medical Device Development Tools program. Her career spans over 25 years within multiple federal agencies, including the FDA, the Department of Health and Human Services, and the National Institutes of Health. She retired from active duty as a Captain of the United States Public Health Service in 2022. Ms. Scharen-Guivel received a Bachelor of Science in Biomedical Engineering and a Master's Degree in Engineering from the Catholic University of America. - Hilda Scharen Guivel，自2022年起任职。Scharen-Guivel女士目前担任圣安东尼医院董事会成员，该医院自2025年1月起成为社区拥有的Baycare卫生系统的一部分。她自2025年2月起担任圣安东尼（i）临床卓越委员会成员，自2024年2月起担任（ii）财务委员会成员。从2022年1月至今，Scharen-Guivel女士在坦帕湾技术孵化器（TBTI）专业委员会任职，并担任南佛罗里达大学（“USF”）和USF Connect的特邀发言人。Scharen-Guivel女士于2017年至2022年担任美国食品和药物管理局（“FDA”）器械和放射健康中心的项目主任，在那里她领导并实施了新的医疗器械开发工具计划。她的职业生涯跨越了25年，在多个联邦机构任职，包括FDA、卫生与公众服务部和美国国立卫生研究院。她于2022年从现役退役，担任美国公共卫生服务队长。Scharen-Guivel女士在美国天主教大学获得生物医学工程学士和工程学硕士学位。
- Hilda Scharen Guivel,has served on Board since 2022. Ms. Scharen-Guivel currently serves on the Board of Trustees of St. Anthony's Hospital, part of a community-owned Baycare Health System since January 2025. She has been serving on St. Anthony's (i) Clinical Excellence Committee since February 2025 and (ii) Finance Committee since February 2024. From January 2022 to present, Ms. Scharen-Guivel serves on the Tampa Bay Technology Incubator (TBTI) Council of Professionals, and Guest Speaker to the University of South Florida ("USF") and USF Connect. Ms. Scharen-Guivel served as Program Director of the U.S. Food and Drug Administration (the "FDA") Center of Devices and Radiological Health from 2017 to 2022, where she led and implemented the new Medical Device Development Tools program. Her career spans over 25 years within multiple federal agencies, including the FDA, the Department of Health and Human Services, and the National Institutes of Health. She retired from active duty as a Captain of the United States Public Health Service in 2022. Ms. Scharen-Guivel received a Bachelor of Science in Biomedical Engineering and a Master's Degree in Engineering from the Catholic University of America.
- Joe Kiani
-
Joe Kiani是Masimo公司的创始人，自公司在1989年成立，他就担任首席执行官以及董事会主席。他是持有超过50项专利的发明人，这些发明都关于信号处理、传感器和患者检测，包括发明了measure-through motion 以及low-perfusion pulse 测量法。从1998年到2013年，Kiani先生任职于Saba Software, Inc.董事会，该公司是一家上市交易的软件公司，主要关注于人类资本开发以及管理解决方案。Kiani先生从San Diego State大学获得电机工程学士学位和硕士学位。作为Masimo公司的创始人，以及自1989年担任首席执行官和董事会主席，Kiani先生对Masimo公司的历史、文化以及技术有着充分的理解。
Joe Kiani is the founder of Masimo Corporation, where he served as Chairman and CEO from 1989 until 2024, growing the company into a global leader in non-invasive patient monitoring technologies, particularly pulse oximetry. Mr. Kiani is also the CEO of Willow Laboratories, a health and llness innovator, and Like Minded Labs, a company foced on advanced video technologies, and he serves on the Board of Directors of CDX Medical Technologies, an early-stage respiratory care company. - Joe Kiani是Masimo公司的创始人，自公司在1989年成立，他就担任首席执行官以及董事会主席。他是持有超过50项专利的发明人，这些发明都关于信号处理、传感器和患者检测，包括发明了measure-through motion 以及low-perfusion pulse 测量法。从1998年到2013年，Kiani先生任职于Saba Software, Inc.董事会，该公司是一家上市交易的软件公司，主要关注于人类资本开发以及管理解决方案。Kiani先生从San Diego State大学获得电机工程学士学位和硕士学位。作为Masimo公司的创始人，以及自1989年担任首席执行官和董事会主席，Kiani先生对Masimo公司的历史、文化以及技术有着充分的理解。
- Joe Kiani is the founder of Masimo Corporation, where he served as Chairman and CEO from 1989 until 2024, growing the company into a global leader in non-invasive patient monitoring technologies, particularly pulse oximetry. Mr. Kiani is also the CEO of Willow Laboratories, a health and llness innovator, and Like Minded Labs, a company foced on advanced video technologies, and he serves on the Board of Directors of CDX Medical Technologies, an early-stage respiratory care company.
- Roger Susi
-
Roger Susi，自1992年成立以来一直担任总裁兼首席执行官，直至2019年8月担任首席技术官。2020年5月，苏思先生恢复担任公司总裁兼首席执行官职务。他在医疗器械行业拥有超过40年的管理经验，包括担任Invivo Research Inc.的创始人、董事长和首席执行官，该公司是一家医疗器械公司，也是Invivo Corporation的前身，该公司建立了MRI安全的患者监测。Susi先生于1998年至2000年担任Invivo Corporation的董事，并于1979年至1998年担任Invivo Research Inc.的总裁。Susi先生是一名生物医学工程师，1977年获得凯斯西储大学生物医学工程学士学位。
Roger Susi,served as President and Chief Executive Officer from incorporation in 1992 until August 2019, when he took the role of Chief Technology Officer. In May 2020, Mr. Susi resumed his duties as the Company's President and Chief Executive Officer. He has over 40 years of management experience in the medical device industry, including as a founder, Chairman and Chief Executive Officer of Invivo Research Inc., a medical device company and the predecessor to Invivo Corporation, which established MRI-safe patient monitoring. Mr. Susi served as a director of Invivo Corporation from 1998 through 2000 and as President of Invivo Research Inc., from 1979 through 1998. Mr. Susi is a biomedical engineer and received a B.S. in Biomedical Engineering from Case Western Reserve University in 1977. - Roger Susi，自1992年成立以来一直担任总裁兼首席执行官，直至2019年8月担任首席技术官。2020年5月，苏思先生恢复担任公司总裁兼首席执行官职务。他在医疗器械行业拥有超过40年的管理经验，包括担任Invivo Research Inc.的创始人、董事长和首席执行官，该公司是一家医疗器械公司，也是Invivo Corporation的前身，该公司建立了MRI安全的患者监测。Susi先生于1998年至2000年担任Invivo Corporation的董事，并于1979年至1998年担任Invivo Research Inc.的总裁。Susi先生是一名生物医学工程师，1977年获得凯斯西储大学生物医学工程学士学位。
- Roger Susi,served as President and Chief Executive Officer from incorporation in 1992 until August 2019, when he took the role of Chief Technology Officer. In May 2020, Mr. Susi resumed his duties as the Company's President and Chief Executive Officer. He has over 40 years of management experience in the medical device industry, including as a founder, Chairman and Chief Executive Officer of Invivo Research Inc., a medical device company and the predecessor to Invivo Corporation, which established MRI-safe patient monitoring. Mr. Susi served as a director of Invivo Corporation from 1998 through 2000 and as President of Invivo Research Inc., from 1979 through 1998. Mr. Susi is a biomedical engineer and received a B.S. in Biomedical Engineering from Case Western Reserve University in 1977.
- James Hawkins
-
James Hawkins自2013年12月以来担任董事长。他是Natus Medical, Inc.（医疗设备和软件的主要制造商，新生儿保健、神经学、睡眠、听觉和平衡市场的服务提供商）的总裁和首席执行官。他自2004年以来担任该职位。此外，他目前担任Natus Medical, the Digirad Corporation和IRIDEX Corporation的董事。他服务于Digirad的审计和薪酬委员会（audit and compensation committees），IRIDEX的审计委员会以及提名和治理委员会（audit and nominating and governance committees）。加入Natus之前，他是Invivo Corporation（MRI（核磁共振成像）-安全病人监测的提供商）的总裁，首席执行官和董事。此前，他是Sensor Control Corporation的首席财务官。他获得圣克拉拉大学（Santa Clara University）的电子商务学士学位，持有旧金山州立大学（San Francisco State University）的工商管理硕士学位。
James Hawkins,previously served on Board from 2013 to 2016 and was re-elected to serve on Board in 2019. From 2019 to the present, Mr. Hawkins held no other positions except for serving on Board of Directors and the board of directors of OSI Systems, Inc. and AudioEye, Inc. From 2004 to 2018, Mr. Hawkins was the President and Chief Executive Officer of Natus Medical, Inc., a leading manufacturer of medical devices and software and a service provider for the newborn care, neurology, sleep, hearing and balance markets. Prior to Natus Medical, Inc., Mr. Hawkins was President, Chief Executive Officer, and a Director of Invivo Corporation, a provider of MRI-safe patient monitoring and the Chief Financial Officer of Sensor Control Corporation. Mr. Hawkins earned his undergraduate degree in Business Commerce from Santa Clara University and holds an M.B.A. from San Francisco State University. - James Hawkins自2013年12月以来担任董事长。他是Natus Medical, Inc.（医疗设备和软件的主要制造商，新生儿保健、神经学、睡眠、听觉和平衡市场的服务提供商）的总裁和首席执行官。他自2004年以来担任该职位。此外，他目前担任Natus Medical, the Digirad Corporation和IRIDEX Corporation的董事。他服务于Digirad的审计和薪酬委员会（audit and compensation committees），IRIDEX的审计委员会以及提名和治理委员会（audit and nominating and governance committees）。加入Natus之前，他是Invivo Corporation（MRI（核磁共振成像）-安全病人监测的提供商）的总裁，首席执行官和董事。此前，他是Sensor Control Corporation的首席财务官。他获得圣克拉拉大学（Santa Clara University）的电子商务学士学位，持有旧金山州立大学（San Francisco State University）的工商管理硕士学位。
- James Hawkins,previously served on Board from 2013 to 2016 and was re-elected to serve on Board in 2019. From 2019 to the present, Mr. Hawkins held no other positions except for serving on Board of Directors and the board of directors of OSI Systems, Inc. and AudioEye, Inc. From 2004 to 2018, Mr. Hawkins was the President and Chief Executive Officer of Natus Medical, Inc., a leading manufacturer of medical devices and software and a service provider for the newborn care, neurology, sleep, hearing and balance markets. Prior to Natus Medical, Inc., Mr. Hawkins was President, Chief Executive Officer, and a Director of Invivo Corporation, a provider of MRI-safe patient monitoring and the Chief Financial Officer of Sensor Control Corporation. Mr. Hawkins earned his undergraduate degree in Business Commerce from Santa Clara University and holds an M.B.A. from San Francisco State University.
- Monty Allen
-
Monty Allen，自2014年起担任董事会成员。从2011年到2024年，Allen先生曾作为财务顾问服务于多家企业。Allen先生拥有超过40年的会计和财务经验，包括曾担任生物技术、医疗和光学技术领域的三家上市公司的首席财务官。Allen先生是佛罗里达州的一名持牌注册会计师。Allen先生在佛罗里达州立大学获得了会计、金融和跨国商业学士学位，并在哈佛大学获得了综合管理硕士学位。
Monty Allen,has served as a member of Board since 2014. From 2011 to 2024, Mr. Allen has served several businesses as a finance consultant. Mr. Allen has more than 40 years of accounting and finance experience including service as the Chief Financial Officer of three publicly held companies in biotech, medical and optical technologies. Mr. Allen is a licensed CPA in Florida. Mr. Allen received a B.S. in Accounting, Finance, and Multinational Business from Florida State University and an M.B.A. in General Management from Harvard University. - Monty Allen，自2014年起担任董事会成员。从2011年到2024年，Allen先生曾作为财务顾问服务于多家企业。Allen先生拥有超过40年的会计和财务经验，包括曾担任生物技术、医疗和光学技术领域的三家上市公司的首席财务官。Allen先生是佛罗里达州的一名持牌注册会计师。Allen先生在佛罗里达州立大学获得了会计、金融和跨国商业学士学位，并在哈佛大学获得了综合管理硕士学位。
- Monty Allen,has served as a member of Board since 2014. From 2011 to 2024, Mr. Allen has served several businesses as a finance consultant. Mr. Allen has more than 40 years of accounting and finance experience including service as the Chief Financial Officer of three publicly held companies in biotech, medical and optical technologies. Mr. Allen is a licensed CPA in Florida. Mr. Allen received a B.S. in Accounting, Finance, and Multinational Business from Florida State University and an M.B.A. in General Management from Harvard University.
高管简历
中英对照 | 中文 | 英文- John Glenn
John Glenn，自2022年起担任首席财务官。Glenn先生是一位财务主管，在指导公共和私营公司的公司财务活动方面拥有超过30年的经验，并在显着增长的企业价值方面有着既定的记录。Glenn先生在获得公司任命之前，于2018年至2022年期间担任Esko Bionics的首席财务官。他在此之前的经验还包括在其他几家公司担任首席财务官，包括，Sonendo、Armetheon、Solta Medical、Cholestech和Invivo Corporation。Glenn先生在圣克拉拉大学获得金融MBA学位，在内华达大学获得工商管理学士学位。
John Glenn,has served as Chief Financial Officer since 2022. Mr. Glenn is a Financial Executive with over 30 years of experience directing public and private companies' corporate finance activities and an established record in significantly growing enterprise value. Before his appointment at the Company, Mr. Glenn served as Chief Financial Officer at Esko Bionics from 2018 to 2022. His prior experience also includes serving as Chief Financial Officer at several other companies, including, Sonendo, Armetheon, Solta Medical, Cholestech, and Invivo Corporation. Mr. Glenn received his MBA in Finance from Santa Clara University and his B.S. in Business Administration from the University of Nevada.- John Glenn，自2022年起担任首席财务官。Glenn先生是一位财务主管，在指导公共和私营公司的公司财务活动方面拥有超过30年的经验，并在显着增长的企业价值方面有着既定的记录。Glenn先生在获得公司任命之前，于2018年至2022年期间担任Esko Bionics的首席财务官。他在此之前的经验还包括在其他几家公司担任首席财务官，包括，Sonendo、Armetheon、Solta Medical、Cholestech和Invivo Corporation。Glenn先生在圣克拉拉大学获得金融MBA学位，在内华达大学获得工商管理学士学位。
- John Glenn,has served as Chief Financial Officer since 2022. Mr. Glenn is a Financial Executive with over 30 years of experience directing public and private companies' corporate finance activities and an established record in significantly growing enterprise value. Before his appointment at the Company, Mr. Glenn served as Chief Financial Officer at Esko Bionics from 2018 to 2022. His prior experience also includes serving as Chief Financial Officer at several other companies, including, Sonendo, Armetheon, Solta Medical, Cholestech, and Invivo Corporation. Mr. Glenn received his MBA in Finance from Santa Clara University and his B.S. in Business Administration from the University of Nevada.
- Jeffery Chiprin
Jeffery Chiprin，自2024年起担任首席商务官，在私营和公共部门的医疗技术领域拥有超过30年的高级领导经验。他于1996年加入Invivo公司，曾担任北美销售副总裁六年。Chiprin先生在飞利浦公司担任了14年的销售副总裁，领导一个部门，为影像、肿瘤科和麻醉科的Iradimed Corporation e提供先进的临床解决方案。此后，他于2020年至2023年在Aspect Imaging担任全球销售副总裁，并于2024年在TerraRecon，Inc.担任商业医疗高级副总裁，直到同年晚些时候加入IRADIMED。奇普林先生在加州大学洛杉矶分校获得政治学学士学位。
Jeffery Chiprin,has served as Chief Commercial Officer since 2024 and has over 30 years of senior leadership experience in medical technology in both private and public sectors. He joined Invivo Corporation in 1996 and was the Vice President of North American Sales for six years. Mr. Chiprin served as the Vice President of Sales for 14 years at Philips Corporation, leading a division with advanced clinical solutions for Iradimed Corporation e in the Imaging, Oncology and Anesthesia departments. After that, he served as Vice President of Worldwide Sales at Aspect Imaging from 2020 to 2023 and as Senior Vice President of Commercial Healthcare at TerraRecon, Inc. in 2024 until joining IRADIMED later in the same year. Mr. Chiprin earned his B.A. in Political Science from the University of California at Los Angeles.- Jeffery Chiprin，自2024年起担任首席商务官，在私营和公共部门的医疗技术领域拥有超过30年的高级领导经验。他于1996年加入Invivo公司，曾担任北美销售副总裁六年。Chiprin先生在飞利浦公司担任了14年的销售副总裁，领导一个部门，为影像、肿瘤科和麻醉科的Iradimed Corporation e提供先进的临床解决方案。此后，他于2020年至2023年在Aspect Imaging担任全球销售副总裁，并于2024年在TerraRecon，Inc.担任商业医疗高级副总裁，直到同年晚些时候加入IRADIMED。奇普林先生在加州大学洛杉矶分校获得政治学学士学位。
- Jeffery Chiprin,has served as Chief Commercial Officer since 2024 and has over 30 years of senior leadership experience in medical technology in both private and public sectors. He joined Invivo Corporation in 1996 and was the Vice President of North American Sales for six years. Mr. Chiprin served as the Vice President of Sales for 14 years at Philips Corporation, leading a division with advanced clinical solutions for Iradimed Corporation e in the Imaging, Oncology and Anesthesia departments. After that, he served as Vice President of Worldwide Sales at Aspect Imaging from 2020 to 2023 and as Senior Vice President of Commercial Healthcare at TerraRecon, Inc. in 2024 until joining IRADIMED later in the same year. Mr. Chiprin earned his B.A. in Political Science from the University of California at Los Angeles.
- Roger Susi
Roger Susi，自1992年成立以来一直担任总裁兼首席执行官，直至2019年8月担任首席技术官。2020年5月，苏思先生恢复担任公司总裁兼首席执行官职务。他在医疗器械行业拥有超过40年的管理经验，包括担任Invivo Research Inc.的创始人、董事长和首席执行官，该公司是一家医疗器械公司，也是Invivo Corporation的前身，该公司建立了MRI安全的患者监测。Susi先生于1998年至2000年担任Invivo Corporation的董事，并于1979年至1998年担任Invivo Research Inc.的总裁。Susi先生是一名生物医学工程师，1977年获得凯斯西储大学生物医学工程学士学位。
Roger Susi,served as President and Chief Executive Officer from incorporation in 1992 until August 2019, when he took the role of Chief Technology Officer. In May 2020, Mr. Susi resumed his duties as the Company's President and Chief Executive Officer. He has over 40 years of management experience in the medical device industry, including as a founder, Chairman and Chief Executive Officer of Invivo Research Inc., a medical device company and the predecessor to Invivo Corporation, which established MRI-safe patient monitoring. Mr. Susi served as a director of Invivo Corporation from 1998 through 2000 and as President of Invivo Research Inc., from 1979 through 1998. Mr. Susi is a biomedical engineer and received a B.S. in Biomedical Engineering from Case Western Reserve University in 1977.- Roger Susi，自1992年成立以来一直担任总裁兼首席执行官，直至2019年8月担任首席技术官。2020年5月，苏思先生恢复担任公司总裁兼首席执行官职务。他在医疗器械行业拥有超过40年的管理经验，包括担任Invivo Research Inc.的创始人、董事长和首席执行官，该公司是一家医疗器械公司，也是Invivo Corporation的前身，该公司建立了MRI安全的患者监测。Susi先生于1998年至2000年担任Invivo Corporation的董事，并于1979年至1998年担任Invivo Research Inc.的总裁。Susi先生是一名生物医学工程师，1977年获得凯斯西储大学生物医学工程学士学位。
- Roger Susi,served as President and Chief Executive Officer from incorporation in 1992 until August 2019, when he took the role of Chief Technology Officer. In May 2020, Mr. Susi resumed his duties as the Company's President and Chief Executive Officer. He has over 40 years of management experience in the medical device industry, including as a founder, Chairman and Chief Executive Officer of Invivo Research Inc., a medical device company and the predecessor to Invivo Corporation, which established MRI-safe patient monitoring. Mr. Susi served as a director of Invivo Corporation from 1998 through 2000 and as President of Invivo Research Inc., from 1979 through 1998. Mr. Susi is a biomedical engineer and received a B.S. in Biomedical Engineering from Case Western Reserve University in 1977.